Overview

Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

Status:
Withdrawn
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Illinois at Chicago
Collaborator:
Genentech, Inc.
Treatments:
Ranibizumab